Full-Time

Director – AI Governance and Policy Lead

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$183.8k - $275.7k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Applied Machine Learning
AI Research
AI & Machine Learning
Required Skills
Machine Learning
Risk Management
Requirements
  • Bachelor's or Master's degree in a relevant field, such as computer science, engineering, or public policy. Degrees in related fields such as law, particularly intellectual property and data privacy, are also desired
  • Minimum of 8 years of experience in data governance and/or AI governance, policy, or related fields
  • Knowledge of regulatory and legal requirements related to AI and machine learning in the pharmaceutical industry
  • Experience in leading organizational change management efforts and deploying AI or other technologies
  • Experience in developing policies, procedures, training programs and resources for data governance and/or AI governance
  • Understanding of how AI technologies work at a technical level and ability to explain AI concepts to both technical and non-technical stakeholders
  • Strong analytical and problem-solving skills
  • Excellent communication and interpersonal skills, with the ability to collaborate effectively with cross-functional teams
  • Experience developing and delivering training programs and resources
  • Demonstrated ability to work independently and manage multiple priorities in a fast-paced environment
  • Understanding of the ethical implications of AI technologies and the ability to apply ethical frameworks to real-world scenarios
Responsibilities
  • Develop and oversee implementation of governance policies and frameworks for the ethical and responsible use of AI technologies within the company (including generative AI), in accordance with regulatory and legal requirements, including EU AI act
  • Develop and maintain an AI risk management strategy that identifies and mitigates potential risks associated with the use of AI at the company
  • Establish and maintain excellence in cross-functional partnerships to ensure that AI technologies are developed and deployed in a manner that aligns with the company's values and mission
  • Create and maintain repository for tracking AI initiatives, solutions, vendors and their respective governance statuses
  • Collaborate with technical teams to ensure that AI technologies are designed and developed in a transparent and ethical manner, taking into account potential risks and biases
  • Partner with HR to develop and deliver training programs and resources to educate employees on AI governance policies and best practices
  • Establish and maintain a process for evaluating and approving use of AI (and generative AI) technologies across the company
  • Oversee development and implementation of processes for auditing and monitoring use of AI within the company
  • Work with legal and compliance teams to ensure that AI technologies are deployed in compliance with applicable laws and regulations, including privacy and security requirements
  • Monitor and assess emerging trends and regulatory developments related to AI and machine learning in the pharmaceutical industry, and provide recommendations for policy and governance changes to ensure alignment with industry standards and best practices
  • Facilitate communication and engagement with external stakeholders, including regulatory agencies, industry groups, and non-governmental organizations, to ensure alignment on ethical and responsible use of AI
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself through its commitment to scientific innovation and strategic partnerships, allowing it to address unmet medical needs effectively. The company's goal is to improve the quality of life for patients with severe conditions by bringing transformative treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment label boosts market penetration in Europe.
  • Partnership with Arbor Biotechnologies positions Vertex at the forefront of innovative treatments.
  • Recent investments indicate strong investor confidence in Vertex's growth potential.

What critics are saying

  • Recent layoffs suggest financial or strategic challenges impacting operational capabilities.
  • Discontinuation of diabetes asset indicates difficulty diversifying beyond cystic fibrosis.
  • Reliance on key products like ivacaftor makes Vertex vulnerable to market fluctuations.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's collaboration with Arbor Biotechnologies advances novel ex vivo engineered cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Pharmalive
Jun 11th, 2025
After axing diabetes asset, Vertex lays off 140 staff

After axing diabetes asset, Vertex lays off 140 staff.

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.